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The ultimate therapeutic step in the treatment of hepatic disease is 
the provision of a new liver with or without removal of the affected native 
organ. At the writing of this manuscript, nearly 2000 liver transplants have 
been performed in the United States alone. Probably another 1000 have 
been performed in other parts of the world. 
Two approaches to liver transplantation have been utilized. The first 
consists of the insertion of an extra liver (auxiliary liver transplantation) at 
an ectopic location. This approach leaves the recipient's diseased liver 
intact. The alternative approach to auxiliary hepatic transplantation is 
orthotopic liver transplantation. With this operation, the diseased liver is 
removed, creating a space into which the allograft is transplanted with as 
normal an anatomic reconstruction as is possible based upon the specific 
liver pathology and the prior surgical history of the recipient. 
AUXILIARY LIVER TRANSPLANTATION 
The first attempts at whole liver grafting were auxiliary grafts, carried 
out in 1955. 17. 56 The use of auxiliary grafts was initially attractive because 
of the belief that the sacrifice of the residual function of a failing liver could 
be avoided and would provide some reserve in the event of poor perform-
ance on the part of the liver graft. However, the results obtained with 
auxiliary liver transplantation have heen poorer than those obtained with 
orthotopic liver replacement. The major hypothetical drawback of the 
auxiliary grafts is that they might atrophy and fail to function with time. 
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The extent to which this prediction is valid has not been assessed critically 
became of the lllany other causes of graft failure in the cases in which it 
has been attempted. lIowever, it needs to be stated that the placement of 
extra livers ill nonanatomic locations has been difficult historically with a 
high rate of vascular thromboses and other technical complications being 
experienced in such cases. 
Nevertheless, interest in auxiliary transplantation has stimulated many 
studies about the fate of liver tissue given different types of portal venous 
inflow. 24, 35.4:).48.49 In one such model, splanchnic venous blood is provided 
to one segment of the liver by way of the portal vein, whereas the other 
segments are supplicd with blood from the inferior vena cava. The segments 
receiving flow fi·om the vena cava invariably atrophy, Moreover, this atrophy 
cannot be prevented by arterializing the involved segment. In another 
model, the so called "double liver," blood returning from the pancreas, 
duodenum, and stomach passes to one portion of the liver, while the other 
half of the liver is pcrfused with venous blood returning from the small 
intestine, The segment perfused with blood from the upper abdominal 
viscera remains normal whereas the liver segments perfused with intestinal 
venous blood will atrophy. 
ORTHOTOPIC TRANSPLANTATION 
Since the beginning of the cyclosporine era, more than 1000 patients 
have received an orthotopic liver transplant. The first reported attempts at 
ortbotopic liver transplantation were by Cannon. Subsequently, orthotopic 
liver transplantation has been developed principally by United States 
workers ill Denver, Pittsburgh, and English workers in Cambridge and 
London. -; 27.29,31. :19. 40. 45. 46 The technical problems associated with orthotopic 
liver transplantation and the histopathologic features of liver rejection were 
studied initially in clogs. Subsequently, it was noted that the rejection 
experienced by orthotopic pig liver homografts was relatively mild as 
compared with that experienced by the dog. 
Human orthotopic liver transplantation was first attempted in 1963. 36, 
J-;, 4-; At first, many people considered transplantation for nonneoplastic 
disease to be unjustifiable. Later, advanced nonmalignant liver disease 
bccame an indication for transplantation only after considerable social and 
vocational invalidism as a result of hepatic encephalopathy, variceal hem-
orrhage, hcpatorcnal syndrome, intractable ascites, and a wide variety of 
other complications of hepatic disease had occurred. Unfortunately, in 
many of these early cases, potential recipient deterioration had either 
already occurred or occurred during the evaluation process or during the 
time it took to idcntify an appropriate donor organ, Once begun, hepatic 
decompensation rapidly leads to coma, ann ria, gastrointestinal bleeding, 
amI multiple infections making liver transplantation most difficult, if not 
impossible, 
\Vith continued experience, it became clear that liver transplantation 
is easier for some hepatic diseases and exceptionally difficult in others, 
\Vhatever the underlying hepatic disease might be, however, individuals 
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Table 1. I IIdications for Orthotopic Litoer Transplantation 
Advanced Chronic Liver Disease 
Preduminantly cholestatic diseases 
Primary biliary cirrhosis 
Primary scleroSing cholangitis 
Biliary atresia 
Familial cholestastic syndromes 
Predominantly hepatocellular disease 
Chronic viral-induced liver disease 
Chronic drug-induced liver disease 
Alcoholic liver disease 
Idiopathic autoimmune liver disease 
Predominantly vascular disease 
Budd-Chiari syndrome 
Veno-occlusive disease 
Hepatic Malignancies That Are Not 
Resectable 
Hepatocellular carcinoma 
Cholangiocarcinoma 
Rare nonhepatocellular or bile ductular 
tumors that arise within the hepatic 
parenchyma 
Isolated hepatic metastatic disease 
Carcinoid 
Pancreatic islet cell tumor 
Others 
Fulminant Hepatic Failure 
Viral hepatitis 
A, B, D, kon~AI Non-B, EB\', Other 
Drug-induced liver disease 
Halothane 
Gold 
Disulfiram 
Acetaminophen 
Others 
Metabolic liver disease 
Wilson's disease 
Heye's syndrome 
Organic acidurias 
Metabolic Liver Disease 
Alpha-l antitrypsin deficiency 
Wilson's disease 
Homozygous type II hyperlipoproteinemia 
Crigler~kajjar syndrome type I 
Erythropoietic protoporphyria 
U rea cycle deficiencies 
Glycogen storage diseases type I and 1\' 
Tyrosinemia 
Hemochromatosis 
with prior adheSion-forming operations, particularly those in thc upper 
abdomen, have an increased perioperative mortality, especially if the porta 
hepatis has been dissected for either a portal diversion or a biliary tract 
reconstructive procedure. 38 
The principal current indications for liver transplantation are shown in 
Tables I and 2. In children, biliary atresia is the leading indication. In 
adults, postnecrotic cirrhosis has been the most frequent indication, Other 
diseases in adults for which transplantation has been utilized include 
primary biliary cirrhosis, sclerosing cholangitis, and a large Humber of 
metabolic liver diseases, 
In 10 per cent of early operations either a thrombosed or hypoplastic 
portal vein existed. As a result of this experience, all potential liver 
transplant candidates currently are studied with ultrasonography to define 
the status of their portal vein preoperatively. Whenever the results with 
ultrasonography are either equivocal or consistent with absence of the 
portal vein, either portal venography as part of a superior mesenteric 
arteriographic study or an NMR study is obtained to visualize the portal 
vein. This experience relative to the status of the portal vein as well as 
experience with other problems encountered has dictated the format of a 
formal pretransplant evaluation for all liver transplant candidates seen at 
the University of Pittsburgh. The evaluation has the following as its six 
goals: (1) confirmation of the specific hepatic disease diagnosis; (2) docu-
mentation of the disease severity; (3) measurement of the recipient's 
intellectual and psychiatric status; (4) an assessment of any abnormalities of 
extrahepatic organ systems that might adversely affect transplantation; (5) a 
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Table 2. Clinical and Biochemical Indications for 
Liver Transplantation Candidacy 
Acute Liver Failure 
Bilirubin > 10-20 mg/dl and increasing 
Prothrombin time> 10 seconds above control and 
increasing . 
Progressive encephalopathy of at least Grade 3 
Chronic Liver Disease 
Cholestatic liver disease 
Bilirubin> 10-15 mg/dl 
Intractable pruritus 
Intractable bone disease 
Hepatocellular liver disease 
Albumin < 2.5 g/dl 
Hepatic encephalopathy 
Prothrombin time > 5 seconds above control 
Factors common to both types of liver disease 
Hepatorenal syndrome 
Recurrent spontaneous bacterial peritonitis 
Intractable ascites 
Recurrent episodes of biliary sepsis 
Development of a hepatocellular carcinoma 
determination of whether liver replacement is anatomically possible; and 
finally (6) whether alternative procedure or therapy might not be possible 
instead of liver transplantation. 38, 55 
Because diseased livers due to hepatocellular disease are small, a donor 
with a smaller liver and therefore of smaller stature (10 kg or more less 
than the recipient) may be sought. This cannot be a generalization, ho~everI 
as hepatomegaly is characteristic of so~eK hepatic diseases: s.uch, as Kpnm~ry 
biliary cirrhosis and sclerosing cholangItis. Thus, the reCIpIent s lIver SIze 
should always be estimated with imaging techniques. 
Because of the combined effects of coagulopathy and portal hyperten-
sion in patients with liver failure, hemostasis is often difficult to obtain until 
the hypertensive portal venous system is decompressed either through the 
liver graft or by way of a portal systemic bypass system. Once the new 
liver is in place, however, improved coagulation can be expected. 
The transplant procedure can require large numbers of units of blood 
in patients with severe portal hypertension. Adhesi~ns present from pre-
vious abdominal operations, other than portal-systemIc shunts, often create 
particularly fragile venous collaterals that tend to bleed profusely. If a 
surgically created portal caval shunt exists, the anastomosis must be t~ken 
down to adequately revascularize the graft. f~ such cases, the resld';Ial 
portal vein is frequently sclerotic and m~y be d~fficult to ~se: When prIor 
portal venous shunting has been accomplIshed With a functIonmg mesocaval 
shunt or splenorenal shunt, the shunt must be closed to ~revent a "steal" 
syndrome that would otherwise deprive the liver graft of Its portal v~nous 
blood supply. In some cases, a prior shunt will preclude transplantatlO.n ~s 
a result of retrograde portal vein thrombosis or because the portal vem IS 
rendered abnormal by the aftermath of the diversion. 
Transplantation for hepatitis B-induced chronic liver disease has been 
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and continues to be a clinical problem. The antigen titer in the few patients 
srudied has been reduced only temporarily after operation, suggesting that 
the excised liver is the principal, but not the sole, reservoir for the virus 
in the body. 14 Complete clearing of the virus has not been achieved dpspite 
treatment with large quantities of hyperimmune globulin. ~·foreo"erI a 
course of preoperative immunization with an HBsAg vaccine has failed also 
to result in viral clearance either before or after successful transplantation. 
CURRENT SPECIFIC INDICATIONS FOR LIVER 
TRANSPLANTATION . 
Biliary Atresia 
The prevalence of biliary atresia has been estimated to be hetwpen 1 
in 7000 and 1 in 13,000 live births. Most, but not all, children with biliary 
atresia should be candidates for liver transplantation. 10 The exceptions are 
those who have severe associated anomalies of other organ systems that 
prohibit meaningful life or prohibit transplantation. Such are estimated to 
occur in about 15 per cent of cases. 
All children with biliary atresia need to be evaluated carefully. Some 
have unexpected intraabdominal venous and intestinal anomalies that either 
prohibit liver transplantation or make it very difficult. 13. 41 One characteristic 
cluster of anomalies includes an absent vena cava, a preduodenal portal 
vein, a hepatic artery arising from the superior mesenteric vein, and 
intestinal malrotation. 
Because of recurrent episodes of cholangitis after a standard porticoen-
terostomy (Kasai procedure), an increasing number of children with biliary 
atresia have had multiple abdominal operations, particularly diverting 
jejunostomies prior to transplantation. These often require closure because 
of bleeding or stomal ulceration. The net result of such additional surgery 
has been that transplantation becomes more difficult because of the highly 
vascular adhesions that develop in the hilar area of these children. 
Hepatic Malignancy 
The prognosis for patients with a nonfibrolamellar hepatoma that is not 
resectable without transplantation is highly predictahle, with death O('Cur-
ring within 6 months. When first seen, patients with hepatoma may he in 
good physical condition, and at least some do not deteriorate rapidly while 
waiting for a donor organ. More importantly, portal hypertension is seldom 
severe in such cases if the livers do not have cirrhosis. Finally, IJPC'UusP 
livers filled with tumor are either normal in size or more usually enlarged. 
the technical demands of the surgical procedure per se tend to hp simple 
in comparison to that experienced in individuals with advanced cirrhosis. 
Unfortunately, a recurrence of tumor after transplantation is common 
and has dampened the initial enthusiasm for liver transplantation for this 
particular indication. 3, 34, 36. 37. 47 Eighty-five per cent of the recipients 
transplanted in an effort to treat hepatocellular carcinomas, who lh'e long 
enough for occult residual tumor to be evident, develop overt recurrent 
\ 
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disease. Moreover, such recurrent disease is the principal cause of death 
in these recipients. The situation is even worse for those with cholangiolar 
carcinoma. All such recipients have died of recurrent cholangiolar carci-
noma, usually in less than a year. A categorical exclusion of tumor cases 
based upon this less than ideal experience with hepatic malignancy should 
not be the rule, however, because primary hepatocellular carcinomas found 
incidentally in organs removed for cirrhosis have been cured of their 
malignancy as a result of transplantation. One such patient has been followed 
postoperatively for more than 18 years. 
Postnecrotic Cirrhosis 
Individuals with postnecrotic cirrhosis due to viral, autoimmune, or 
cryptogenic mechanisms are frequently candidates for liver transplantation, 
particularly if they have had any of the many complications that presage 
death in individuals with advanced hepatocellular liver disease, such as 
spontaneous bacterial peritonitis, hepatorenal syndrome, recurrent variceal 
bleeding, or they have had recurrent episodes of hepatic encephalopathy 
or advanced synthetic dysfunction characterized by hypoalbuminemia and 
coagulopathy. In general, these cases are very difficult technically because 
of the combination of intense portal hypertension and coagulopathy. None-
theless, as a group they represent about one third or more of all adult liver 
transplant cases. 
Alpha-I-Antitrypsin Deficiency 
The issues of case selection and surgical technique for this metabolic 
liver disease are the same as those for patients with postnecrotic cirrhosis, 
except that care should be taken to pelfonn the transplant prior to the 
development of irreversible pulmonary disease. After successful operation, 
the protease inhibitor phenotvpe of the recipient converts to that of the 
donor and depressed serum alpha-I-antitrypsin levels become normal. 
Other Metabolic Diseases of the Liver 
A metabolic "cure" following liver transplantation either has been 
proven or presumed in children with type I and IV glycogen storage 
disease, tyrosinemia, Wilson's disease, and a host of other inborn errors. 
Most, but not all, of the characteristic metabolic perturbations of these 
metabolic disorders are corrected after liver transplantation. 9• 13. 18.2:3.38.58 
Alcoholic Liver Disease 
Disease of the lungs amI a variety of other organs, particularly the 
brain, are common in alcoholics with endstage liver disease. Following 
s\lccessful transplantation, noncompliance and recidivism can be a problem. 
Despite these problems, alcoholics have been transplanted and almost all 
have staved sober for prolonged periods. A "reasonable" period of alcohol 
abstinen~c prior to liver transplantation is a desirable condition but is not 
essential for transplant candidacy in all alcoholics. Certainly, those alcoholics 
who adhere to a rehabilitation program and yet bil to regain adequate 
hepatic function should be offered transplantation. 
DesIJite the many potential social and political issues relative to the 
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wider application of liver transplantation for alcoholic cirrhosis, this indi-
cation for liver transplantation is expected to expand. Our vie\\' is that 
alcoholism is a treatable disease, not a vice. 
Primary Biliary Cirrhosis (PBC) 
Transplantation for PBC is technically easier to perform than it is for 
most other indications. The liver is either normal in size or pnlargecl, 
venous collaterals are not excessive, and occlusion of the H'cipient portal 
vein and vena cava during the anhepatic phase of the procedme may be 
well tolerated in such recipients. Recurrences of PBe after s\lccessful 
transplantation have been described, but these claims have not lweI] 
confirmed. B• 11,30.54 Thus for the immediate future, PBe will certainly 
continue to be an important indication for liver transplantatioll. 
Primary Sclerosing Cholangitis (PSC) 
The indications for liver transplantation for PSC are identical to those 
for PBC, except that many of these patients have had prior biliary tract 
surgical procedures that make the recipient hepatectomy technically more 
difficult.25 Whether recurrence of the original disease happens in the 
allograft liver is currently uncertain. Moreover. the role. if any. of the 
presence of associated inflammatory bowel disease (especially u1cerathT 
colitis) in the development of recurrent disease or even transplant cancliclac\-
and the risk of a posttransplant neoplastic discase (colon cancer) are 
currently unknown. 
Secondary Biliary Cirrhosis 
The initiating event in these cases is usually incomplete hiliary tract 
obstruction precipitated as a consequence of a series of ullsuccessfll I 
attempts at earlier biliary tract reconstruction follOWing one or another 
complicated biliary tract operation. The technical problems experienced hv 
the transplant surgeons during the procedure can he enormons. These arise 
both as a result of the altered anatomy and as a result of the 1lI1lllerOliS 
adhesions and the portal hypertension that are present. The biliary sepsis 
present in such cases also increases the surgical risk. 
Budd-Chiari Syndrome 
The fact that portal-systemic diversion by decompressing the lher 
improves hepatic function in some cases and keeps some patients with the 
Budd-Chiari syndrome away from transplantation creates a dilemlllH. "-lam 
patients with the Budd-Chiari syndrome referred for transplalltatioll will 
have had a prior side-to-side portal-caval shunting procedure. In such cases. 
the shunt must be taken down at the time of transplantatioll. This can he 
very difficult, frequently requires a portal vein graft, or makes transplan-
tation impossible. Whether portal diversion is ever indicated Ell Budd-
Chiari syndrome now that liver replacement is a reasonable option is still 
an open question. ~ 
,.{, 
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Table 3. Contrailldications for Liver Transplantation 
Absolute contraindications 
Active sepsis outside the hepatobiliary tree 
Metastatic hepatobiliary malignancy 
Advanced cardiopulmonary disease 
AIDS 
Relative contraindications 
Advanced chronic renal disease 
Age greater than 60 years 
Portal vein thrombosis 
Cholangiocarcinoma 
Hypoxemia with intrapulmonary right to left shunts 
HBgAg and HBeAg positivity 
Prior portacaval shunting procedure 
Prior complex hepatobiliary surgery 
HIV positivity without clinical AIDS 
CONTRAINDICATIONS TO UVER TRANSPLANTATION 
The current list of contraindications for liver transplantation is shown 
in Table 3. None of these is absolute, although they may be very powerful. 
For example, preexisting systemic or local infections create highly unfavor-
able conditions, as do diseases of organs other than the liver, such as 
coexisting severe heart disease or a history of sociopathic behavior (e.g., 
alcoholism or drug ahuse). 
ORGAN PROCUREMENT AND PRESERVATION 
In most transplantation centers in the United States, the criteria of 
brain death based on the concept of irreversible brain injury have been 
accepted. Under thesc conditions and with an ideal cadaveric clonor, the 
interval of normothermic ischemic injury is reduced essentially to zero. 
Fortunately, public acceptance of these conditions of organ removal has 
been widespread. Advances have been made in the field of multiple organ 
harvesting also. 
Donor cardiovascular instability, a need for excessive vasopressor 
support, a long period (several days) between initial injury and the pro-
nouncement of brain death or deterioration of renal function can suggest 
that the donor organs may be less than ideal as allografts. Another common 
explanation for poor liver graft function is either inadequate preservation 
or preexisting hepatic disease. The former is becoming less of a problem 
as a result of the use of the University of Wisconsin's organ preservation 
solution. The latter is also becoming less common as a result of better 
screening of potential donors. 
Assuming that donor selection is appropriate, the surgical removal of 
a good donor organ for transplantation depends upon performing a techni-
cally pedect operation that includes recognizing any of the numerous 
anomalies of the hepatic arterial supply and avoiding warm ischemia. The 
first of these requirements is dependent on the knowledge and skill of the 
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Table 4. Histologic Features that Disfitlgllish Clmmir Rejecfioll.frolll 
Recun-enf Priml1l'Y Biliat·y Cirrhosis 
Primary Biliary Cirrhosis 
Portal infiltrate with lymphocytes 
Fibrosis v.;th cirrhosis 
Granuloma 
Active periportal piecemeal necrosis 
No endothelialitis 
No arterial disease 
Rejection 
Mixed portal inflammatory cells, eosinophils, IVlllphoevtes. and 
polymorphQn uclear cells '. 
No cirrhosis, but often fibrosis 
Active portal and hepatic vein endothelialitis 
Subendothelial foam cells often with arterial thromhosis 
Little or no periportal piecemeal necrosis 
No granuloma 
9 
surge~nK The second is also surgeon dependent and can be met by avoiding 
occlUSIOn of the blood supply during the dissection. The maximulIl cold 
ischemia time that still allows predictable and adequate graft function using 
the recently developed University of Wisconsin liver pelfusate sol1ltion is 
probably well beyond 12 hours and closer to 24 hours. 
TISSUE MATCHING AND LIVER TRANSPLANTATION 
Waiting for a good match at the A, B, and DR loci of the r-IIlC 
complex is currently not practical and probably will never be practical for 
liver transplantation because of the precarious medical condition most lin'!' 
transplant recipients are in prior to transplantation. It is of some interest 
that hepatic transplantation has been performed by both the Pittsburgh 
group and the Cambridge-King's College team despite a positive Cytotox.ic 
cross-match. 4, 6.16.20.51.53 Hyperacute rejection of the grafted liver 11l{s either 
not been seen or is markedly reduced in severity as compare(l to that SE'f'lI 
with renal grafts. In animal models of liver transplantation in which the 
recipient has performed heterospecific cytotoxic humoral antibodies, anti-
body-initiated rejection of the liver has been reported, but it occurs at a 
much slower rate than it does with the kidney or heart (Table .f). 'I The 
mechanisms responsible for graft destruction ill ABO-incompatihle lin'! 
transplants are not well understood, but it seems certain that antigraft 
isoagglutinins playa role in accelerated if not hyperacute rejections. D~rhc 
reasons why such grafts can be used despite positive cytotoxic cross matches 
and without a clinical episode of hyperacute rejection remains to he 
explained. 
RECIPIENT PREPARATION AND THE TRANSPLANT 
PROCEDURE 
Paracentesis andlor thoracentesis are freqllently required before gen-
eral anesthesia in liver transplant recipients. Transfusions of hlood and 
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albumin are often useful. If fi'esh whole blood, fresh frozen plasma, or 
platelets are given, improvement in the preoperative coagulation status of 
the recipient is usually possible preoperatively. 
PORTAL VENOUS BYPASS AND LIVER TRANSPLANTATION 
Usually portal and vena caval occlusion can be tolerated during the 
45- to gO-minute anhepatic phase of the operation despite major reductions 
in the cardiac output and the obligate hypotension that follows portal vein 
and vena caval clampingY The ease at which these vessels can be occluded 
has been shown to be dependent upon the degree of collateral circulation 
that has developed and allows venous return to occur despite large vessel 
occlusion. If severe hypotension occurs when cross-clamping either of these 
vessels, a bypass system must be used. 4• 31 
The fact that most patients can survive portal and inferior vena caval 
cross-clamping has created an impression that this practice is safe. When 
portal cross-clamping is performed without a bypass, the intestine becomes 
progressively boggy and edematous and tends to weep into the peritoneal 
cavity. Subsequently, the recipient often suffers from third space fluid 
losses and peritoneal contamination with the development of enteric bac-
terial and fungal infections. It is easy to imagine how the kidneys can be 
damaged by occluding the vena cava. The extent to which anyone of these 
complex physiologic events contributes to the high perioperative mortality 
of liver transplantation has not been delineated until recently. With the 
routine use of a "heparin free" venous bypass system, the transplant 
operation can be performed under controlled circumstances and the rate at 
which a variety of postoperative complications are experienced is .reduced 
dramatically. As a result, patient survival is increased. The venovenous 
bypass has changed the technical strategy of liver transplantation in several 
other important ways. In the past, when time was a critical factor during 
the anhepatic phase, it was often impossible to obtain meticulous hemosta-
sis. \"'hen the venovenous bypass is lIsed, hemostatic techniques can be 
applied and by doing so, most bleeding can be controlled. Moreover, the 
use of a venous bypass system results in improved intraoperative cardio-
vascular stahility, preservation of renal fUllction by avoiclance of renal vein 
hypertension, excessive blood loss, and subsequent infections. 
OPERATIVE PROBLEMS 
Inadequate Recipient Artery 
Hepatic transplant surgeons must be ready to use arterial grafts should 
the recipient hepatic artery be either too small or inconveniently located 
to permit an adequate anastomosis. The easiest solution to such problems 
is to rearterialize the homograft from the recipient's abdominal aorta, 
inferior to the origin of the renal arteries. The extra length of vessel 
required to reach this location can be obtained most easily by using the 
donor common iliac artery after ligating the hypogastric artery. 
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Portal Vein Problems 
) J 
. If portal ven~us thrombosis, sclerosis, or hypoplasia is plTSf'nt and 
ll1,:,olves the splel1lc and superior mesenteric veins, the confluence of these 
veK1l1~ mu~t be dissected free from the pancreas. A cloaca call be createl] at 
thIS Jtll1ctlOn to which an iliac vein graft can be anastomosed to pn)\"idc fllf' 
added length required to reach the homograft portal vein. Without such 
venous grafts, patients would die in the operating room. 
Biliary Tract Reconstruction 
. Many of the technical complications experienced in the carl, deWS ()f 
lIver transplantation were associated with biliary tract reconstructh·m. Often 
these complications were not recognized until quite late in the postoperative 
Course. As a result, they ~ere as~ociated with abscess fimnation, cholangitis, 
an~ other forms of hepatic sepSIS that contributed directly to the death of 
patfen~sK Our current practice is to create a choledochocholet!ochal anas 
tomosIS, or if prior biliary tract surgery has been pelformecl, a Roux-cll-Y 
choledochojejullostomy. The homograft common duct should be cut high 
eno~gh so that its distal. end is well arterialized from the liver. A naton;-ic 
studIes have shown that the blood supply to the graft bile dud is de-
pendent upon retrograde perfusion from hilar vessels. Late intra- and 
extrahepatic biliary strictures are common if the arterial hlood supph- is lIut 
adequate. 26, 52 . 
Other Operative Problems 
Coagulation defects must be anticipated in all cases. The blccdilltf 
~xperienced intraoperatively can be aggravated by fIhrinolysis. Fihrinohsi; 
IS ~ nonspecific finding th~t can .be caused by ischemic injury of the gl:aft, 
or It ma?, represent. a l~allffestahon of humoral rejection. Bleeding control 
starts with suture lIgation and cautery. With the new li\cr in plact' f he 
portal system ca~ be decompressed through the ne,v orgall, elimillating 
por~al h):pertensIOn as an additional contributing t:"1etor for the hleedillg. 
MeanwhIle, platelets, fresh frozen plasma, and blood constitllcn ts shot! It! 
be transfused as necessary. 
LATE POSTOPERATIVE PROBLEMS 
Major Problems 
. TI?e list oflate complications includes peritonitis with or without bowel 
mfarct~onI bile lea~s al~d/or .biliary obstruction, pancreatitis, pulmonar\ 
embolI,. eKxtraabdol~lflalK mfectIons, and psychosis. The most importallt iSSllc 
for r~Clp~el1t surVIval IS the ability to control rejection. ClllTE'nth-. the 
~ombmatlln of cyclosporine with steroids is the most common h: lIsed 
Immunosuppressive regimen. Adjuvants to this combination inclucie anti-
lymphocyte or anti thymocyte globulins (ALG or ATG) and, more recenth-. 
monoclonal antithymocyte globulin Elhq~FK . 
Nephrotoxicity is the most serious side effect of cvc1osporine lise. 
Fortunately, the renal dysfunction seen with cyclosporine usually can he 
iil.i." 
,t 
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reversed with appropriate reduction of the dose. Gum hyperplasia, tremor, 
hirsutism, regional flushing, vague abdominal discomfort, seizures, and the 
development of breast fibroadenomas are other known side effects. Although 
hepatotoxicity has been reported, this untoward effect of cyclosporine has 
rarely been serious in liver transplant recipients and can be controlled by 
dose reduction when it occurs. 22 
A disturbing consequence of immunosuppression with any first line 
agent, including cyclosporine, has been the development of an EBV-related 
lymphoproliferative syndrome and lymphoma. 12 In kidney recipients, the 
risk has been almost the same after the introduction of cyclosporine as 
before. In contrast, the risk of de novo epithelial malignancies with 
cyclosporine may be less than that experienced with previously used 
conventional immunosuppressive regimens and, as yet, very few such 
tumors have been reported in cyclosporine-treated patients. 32 
The first sign of rejection histopathologically in human recipients is 
the occurrence within the liver of lymphoblastoid cells that appear to leave 
the smallest portal vessels throughout the graft and accumulate in the portal 
tracts beneath the endothelial lining of the sinusoids. As a result of this 
cellular infiltration, the sinusoids became progressively narrowed and 
occasionally occluded. As a result, blood flow through the liver can decrease 
with the development of centrilobular ischemia and occasionally necrosis. 12• 
19. 33 In severe cases, this centrilobular necrosis can progress to midzonal 
necrosis, and biochemical liver function rapidly deteriorates. 
Marked centrilobular cholestasis and canalicular cholestasis can occur 
also. A precise pathophysiologic explanation for this cholestasis has not yet 
been established, but it is almost certainly a manifestation of rejection. 
With chronic rejection, the intralobular bile ducts vanish. 12. 33 Fibrosis 
develops and can progress to a true portal cirrhosis in some cases. A 
characteristic feature of the chronic rejection process is intimal and subin-
timal vascular thickening. Hepatic blood flow is reduced in cases with 
severe rejection, making the ischemic liver graft potentially susceptible to 
bacterial invasion. 2. 15. 42 
Currently the clinical diagnosis of chronic rejection is restricted to 
those patients whose graft biopsies demonstrate either arterial intimal 
thickening, hepatic fibrosis, or bile duct paucity. The morphologic findings 
of "chronic" rejection are not related directly to the postoperative interval 
and can be seen within the first few postoperative months. The clinical 
manifestations of chronic rejection are similar to those of chronic liver 
failure from any cause. In contrast to the process of "acute" hepatic 
rejection, "chronic" rejection does not respond to increased immuno-
suppression. 
Causes of Post-Liver Transplantation Mortality 
The greatest mortality experienced after liver transplantation occurs 
early, usually within the first few months following the procedure. This has 
been both with liver transplantation under conventional immunosuppres-
sion and with cyclosporine-steroid regimens. Detailed analyses of the causes 
for this early mortality have been published. The dominant pathologic 
diagnoses in grafts that fail are rejection, biliary obstruction, recurrent 
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carcinoma, HBV infection, and recurrent original disease occurring less 
often. 2. 12 
The time at which changes in current postoperative managell]('nt are 
most likely to produce a substantial reduction in futllle mortalih- figllles is 
during the immediate perioperative period. . . 
Retransplantation 
When a transplanted liver fails, aggressive attempts at retransplantatiol1 
offer the only chance for survival. One of the most commonly seen judgment 
errors in liver transplantation has been to attempt to gain improvement in 
hepatic function with greater and greater degrees of immunosuppression 
until the chance for retransplantation is lost as a result of scpsis. Retrans-
plantation, when performed early, is surprisingly easy to do. The procedure 
is greatly simplified by retaining vascular cuffs from the supra- and iJtfI-a-
hepatic vena cavae and less commonly from the portal vein of the failing 
graft. Total retransplantation operative time can be as little as .'3 to 4 hours, 
if the primary operation has been recent. 
FACTORS THAT AFFECT SURVIVAL 
Certain risk factors have been examined for their effect on sllnhal. 
Among the more important factors has been age. Pediatric recipients 
throughout the entire history of liver transplantation have fared better b\ 
a few percentage points than have adults. Two high-risk diseases in adult's 
have been identified. Specifically survival with postnecrotic cirrhosis and 
with primary hepatic tumors is less than it is for any othcr indication. With 
cirrhosis, the principal problems have been the numerous surgical diffic1l1-
t~es caused by the pathologic process (coagulopathy and portal hyperten-
SiOn), the poor condition of the cirrhotic patient, and the universal retmn 
of the original B-virus-induced disease in HBV carriers. In patients \"itl! 
primary hepatic malignancy the early mortality is low, with more than 80 
per cent of the recipients alive at 6 months. Unfortunately a stead\' decline 
occurs thereafter as a result of recurrent tumor. . 
WHERE ARE WE GOING? 
The future of liver transplantation is bright. Clearly as a result of 
increasing experience, concept development and the formation of principles 
of liver disease development, progression and therapy are to he expected. 
Currently, it is generally believed that specific liver diseases require specific 
therapies. In the future, subtypes of one or another complication of )i\eJ' 
disease, such as hepatic encephalopathy, will require specific and diff~rent 
therapeutic modalities. Crisis management in the field of liver disease has 
been and will continue to be replaced by carefully thought out and s('ledec! 
therapies that will be initiated not in response to, but ill an effort to prc\ellt 
the development of a complication of liver disease. Nowherc wou\(1 the 
potential for prophylaxis be greater than in alcoholics or in B virus carriprs. 
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Such developments should lead to fewer transplants being performed 
for end stage liver disease and more being performed for selected indica-
tions. As the clinical arena of liver disease shifts from crisis management to 
disease control and the application of specific therapies for specific indica-
tions, one or more artificial "livers," ""hich pelform one or 1110re "hepatic 
functions" will be developed. As a result, liver transplantation for fulminant 
hepatic failure will be utilized less often, but will be applied more frequently 
for the problem of subacute hepatic failure in patients who have "flunked" 
a trial of interim support. 
It should be noted that liver transplantation not only provides physi-
cians and surgeons with challenges, but it has also provided them with the 
tools to address these challenges. Specifically, liver transplantation centers 
inevitably will become centers of excellence in the knowledge of hepatic 
disease. As a result, patients with liver disease will either seek out Ol" be 
referred to such centers. Thus the epidemiology and natural history of 
poorly defined and as yet unrecognized liver diseases will be identified 
throughout their entire course. The removed organs will provide tissues, 
cells, viruses, DNA, and other materials and agents that are responsible 
for or that modify the liver disease. Patients with new organs and on 
immunosuppressi~e agents will develop old diseases with new faces as well 
as totallv new diseases. 
fss~es relative to hepatic disease complication progression and/or 
reversal following liver transplantation will be addressed. Similarly the 
important issue of disease recurrence in a new organ will be addressed. 
What forces produce these diseases or modif}' their presentation, when ard 
if they recur, will be identified and studied. The information gained will 
provide new insights into the specific pathogenesis of individual liver 
diseases and their complications. 
Concerning the issue of disease recurrence, we already know that 
certain diseases such as the Budd-Chiari syndrome, hepatocellular carci-
noma, and cholangiolar cancer as well as hepatitis B virus positive (DNA +) 
disease reoccur in the allograft. Does NANB hepatic disease reoccur as 
well? Do primary biliary cirrhosis and primary sclerosing cholangitis reoc-
cur? Does autoimmune chronic active hepatitis reoccur? These questions 
remain very difficult to answer ft)!· even the committed hepatologist, 
transplant ;urgcon, and hepatic pathologist. The reason for this marked 
difference in perspective is that these types of physicians recognize the 
problems of specific liver disease identification based upon presently used 
standards. Currently only a few liver diseases are diagnosed, utilizing the 
identification of a specific agent or enzyme defect and have a characteristic 
histopathology and/or clinical course. These diseases can be said to be 
identified utilizing a gold standard. Many more liver diseases are recognized 
as a result of a silver standard, which involves a characteristic and unique 
but not pathognomonic pathology that is often associated with characteristic 
and unique scrologic responses. Unfortunately, no specific agent or patho-
physiologic mechanism of disease has been recognized in these cases. Even 
more discouraging, however, is the fact that many more liver diseases are 
identified utilizing a copper standard. That is, they have a characteristic 
but not unique pathology and no characteristic serologic or biochemical 
1 
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markers. Clearly, utilizing anything but a gold standard Illakes the recog-
nition of disease recurrence, as distinct from the development of a 11('\\ 
disease in a new organ, difficult, if not impossible. 
Additional questions that will be answered as a result of the incrf'asillg 
experience with liver transplantation include the f(ll\owillg. (1) WIn do 
liver rejection and chronic active hepatitis differ so markedly histopatllOlog-
ically when the mechanisms involved appear to be so similar and dependent 
upon an active T cell-dependent immune response? (2) \Vhat is the role of 
cell smface and intracellular organelle antigens in liver disease initiation, 
progression, perpetuation, and possihly disease recurrencc? 
It is expected that new and better methods of rejection control and 
hopefully prevention (tolerance) will be developed. These will include 
methods or techniques of modulating antigen-processing cells (APe cells) 
and suppressor cell numbers, function, and lymphokine modulation/neu-
tralization. 
An alternative to enhanced prevention or control of rejection \,"ill llP 
methods and techniques of initiating, modulating, and selecti\"ely regulating 
hepatocyte and bile ductular cell regeneration. Should controlled rt'gener-
ation be possible, at a rate that equals the losses due to rejectioll. a Tle\\' 
and entirely different state of, or concept of, "tolel·ance" will clevel(lp. 
The knowledge that evolves from attempts to achien' thesE' goals in 
the clinical arena of liver transplantation will be applied also to thc prohlem 
of fulminant hepatic failure. Growth factors or regeneratioll modulators \yill 
be developed and used in patients with this lethal problem. As a re~lfltI 
the number of transplantations for fulminant hepatic failure will be redllcC'd 
and the number of such patients recovering without the need for transplan-
tation (new successes) as well as the number operated upon lin sllbacute 
hepatic failure (persistent therapy failures) will increase. Fortunately, the 
number of the latter will be reduced markedly from that which cnrrenth· 
pertains. 
Finally the organs removed at the time of transplantatioll will proYiclc 
the necessary raw materials for the preparation, characterizatioll, amI 
probable ex-vivo production of somatomedins, osteocalcins, and ll1<lIlY other 
materials that will be used to treat and/or prevent complicatiolls, such a~ 
growth failure and bone disease, that currently characterize patients \\ith 
advanced liver disease. 
Clearly much has been learned from the past. r ... luch continues to he 
done. However, the future is promising. 
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Medical Problems Before and 
After Transplantation 
Vincent]. Dindzans, M.D., Robeli: R. Schade, M.D .. 
and David H. Van Thiel. M.D. 
OrthotopiC liver transplantation has gained acceptance as the only 
effective treatment for patients with advanced liver disease of any etiology. O~ 
This has occurred largely as the result of improvements in immunosuppres-
sion, the surgical technique, and experience. Currently liver transplantation 
is being performed by many surgeons in many different medical centers. 
By definition, candidates for liver transplantation are victims of se\'ere 
liver disease who have experienced many of the medical complications of 
chronic advanced disease. Often they have multiple organ system fililurt,. 
Immediately posttransplantation, these patients are subject to tIl£' many 
complications of a major surgical procedure (liver transplantation) as wdl 
as the consequences of their resolving preoperative medical problems, 
many of which may be exacerbated at least temporarily by the surgical 
procedure. Finally both of these events occur in the presence of imllluno-
suppression. 
The purpose of this article is to first review the medical complicatiolls 
that can occur in a liver transplant candidate regarding the effed these 
complications have on the feasibility and timing of transplantation. Then 
the major medical problems that may occur as a result of liver transplan-
tation will be reviewed. 
MEDICAL PROBLEMS PRIOR TO TRANSPLANTATION 
Despite advances in the application of liver transplantation. the re-
quirements for candidacy have remained fairly constant {Tahle l.l. An 
individual under consideration must have an irreversible, progressiH' liH?r 
disease such that death or unacceptable morbidity are the alternatiyes to 
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